{
 "name": "三鼎生技",
 "slug": "tw-6808",
 "aliases": [
  "三鼎生物科技股份有限公司",
  "3D BIO",
  "6808"
 ],
 "ticker": "6808",
 "industry": "生技醫療業",
 "website": "www.3dglobalbiotech.com.tw",
 "summary": "三鼎生技（6808）是興櫃的生技醫療類股公司，2014 年成立，2020 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "三鼎生物科技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "3D BIO",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2020-12-25",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2014-12-26",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "歐耿良",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "歐耿良",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 778400000,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "www.3dglobalbiotech.com.tw",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽約金：人類角膜緣細胞（LSCs）專利與技術",
   "value": 1000000,
   "unit": "美元",
   "as_of": "2024-06-19",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&year=113&month=all&step=2&seq_no=3&spoke_time=160622&spoke_date=20240619&co_id=6808&TYPEK=rotc",
   "note": "發言日期：2024-06-19；主旨：公告本公司與永鼎醫藥股份有限公司簽訂專屬授權契約；以交付報告為付款條件，非本公告日已收證據。"
  },
  {
   "claim": "里程碑金上限：人類角膜緣細胞（LSCs）專利與技術",
   "value": 4000000,
   "unit": "美元",
   "as_of": "2024-06-19",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&year=113&month=all&step=2&seq_no=3&spoke_time=160622&spoke_date=20240619&co_id=6808&TYPEK=rotc",
   "note": "發言日期：2024-06-19；主旨：公告本公司與永鼎醫藥股份有限公司簽訂專屬授權契約；原文為後續各階段授權金總額，與前述100萬美元簽約金分開；不視為已收。"
  },
  {
   "claim": "授權合作：人類角膜緣細胞（LSCs）專利與技術",
   "value": "永鼎醫藥股份有限公司｜全球｜2024-06-19",
   "unit": "",
   "as_of": "2025-09-05",
   "source": "https://www.3dglobalbiotech.com.tw/news_detail.php?nwno=92",
   "note": "全球範圍據本則2025官網；精確簽約日由MOPS發言日期2024-06-19、主旨「公告本公司與永鼎醫藥股份有限公司簽訂專屬授權契約」交叉核對：https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&year=113&month=all&step=2&seq_no=3&spoke_time=160622&spoke_date=20240619&co_id=6808&TYPEK=rotc"
  },
  {
   "claim": "已收金額（公告日為準）：角膜緣幹細胞外泌體技術",
   "value": 160000000,
   "unit": "新台幣",
   "as_of": "2025-09-05",
   "source": "https://www.3dglobalbiotech.com.tw/news_detail.php?nwno=92",
   "note": "公司2025稿稱已獲取1.6億新台幣簽約金；與2024合約將100萬美元列簽約金、400萬美元列後續階段款的分類不同，未自行換算或重新分類。本筆是較晚公告已收款，不能與其他簽約金或里程碑金相加。"
  },
  {
   "claim": "管線：角膜緣幹細胞外泌體技術",
   "value": "乾眼症、角膜炎等眼科疾病｜動物實驗階段｜全球（授權開發範圍）",
   "unit": "",
   "as_of": "2025-09-05",
   "source": "https://www.3dglobalbiotech.com.tw/news_detail.php?nwno=92",
   "note": "對象：永鼎醫藥；未揭公開藥物代號及NCT；不是已核准療法。"
  },
  {
   "claim": "主要產品：EXH-101（毛囊間質幹細胞外泌體藥物原料）",
   "value": "已接獲FDA通知完成第II類原料藥主檔案（DMF）登記",
   "unit": "",
   "as_of": "2026-06-22",
   "source": "https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&year=115&month=all&step=2&seq_no=2&spoke_time=175303&spoke_date=20260622&co_id=6808&TYPEK=rotc",
   "note": "發言日期：2026-06-22；主旨：公告本公司毛囊間質幹細胞外泌體藥物原料EXH-101，取得美國FDA之第II類DMF登記核可；DMF是原料技術檔案登記，不是FDA核准外泌體新藥上市；未揭DMF號碼與FDA通知原件。"
  },
  {
   "claim": "催化劑：角膜緣幹細胞外泌體技術",
   "value": "啟動人體臨床試驗｜2026（公司預估）｜已公告",
   "unit": "",
   "as_of": "2025-09-05",
   "source": "https://www.3dglobalbiotech.com.tw/news_detail.php?nwno=92",
   "note": "2025-09-05公司公告的舊年度預估；截至2026-10-22未找到啟動更新或可核對的NCT編號；非FDA承諾日期，不代表已啟動或已完成。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-6808.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}